CVM
Neutral signalScored 2026-08-28 Drivers: fundamentals. Moteurs : fondamentaux.
Research, not advice.
À propos
CEL-SCI Corporation
- Nom
- CEL-SCI Corporation
- Secteur
- Healthcare
- Industrie
- Biotechnology
- Bourse
- AMEX
- Capitalisation
- $27.8M
- Employés
- 43
- PDG
- Geert R. Kersten
- Site web
- https://cel-sci.com
- Marché
- ALGSBRNSFGENINMBKZRMRSN
CEL-SCI Corporation (CVM) focuses on the research and development of immune-based therapies to combat cancer and various infectious diseases. Its flagship immunotherapy candidate, Multikine, is currently undergoing Phase III clinical trials for the treatment of head and neck cancer. The company also develops and holds the patent for its preclinical Ligand Epitope Antigen Presentation System (LEAPS), an innovative T-cell modulation technology. This system is designed to stimulate the human immune system to fight a broad range of conditions, including bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and various cancers. CEL-SCI's pipeline further includes LEAPS-H1N1-DC, along with LEAPS COV-19, an experimental therapy targeting the COVID-19 coronavirus. Additionally, the company is advancing CEL-2000 and CEL-4000 as potential treatments for rheumatoid arthritis. In a collaborative effort, CEL-SCI has partnered with the University of Georgia's Center for Vaccines and Immunology to progress the LEAPS COVID-19 immunotherapy. Established in 1983, the company's headquarters are located in Vienna, Virginia.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
ACHAT TOTAL: 100 000 titres (~138 000,00 $ US)
- Insiders
- KERSTEN GEERT R
- Total bought
-
$138,000
Avg buy (VWAP, 90d window) $1.38 vs last close —
- Total sold
-
—
Avg sell (VWAP, 90d window) —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
- Last activity
- 2026-08-25
- Last synced
-
2026-08-31 10:14:36
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-08-25 | KERSTEN GEERT R | Buy · P | 100,000 | $1.38 | $138,000 | Form 4 |
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Neutral signalScored 2026-08-28 Drivers: fundamentals. Moteurs : fondamentaux.
CVM presents a meaningful insider cluster buy signal with moderate confidence (0.7), suggesting management conviction around Multikine Phase 3 data and the FDA confirmatory study pathway; however, the severely…
The first sentence of the analysis written for CVM on 2026-08-28 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Supports a bullish reading. Open-market purchases outweigh sales
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Timing Unavailable or mixed. No stored price series
- Financial indicators Supports a bullish reading. Current ratio 2.26 · operating margin 0.0%
Market snapshot
Financial ratios
| Metric | Trend | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Ebit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Ebitda Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Pretax Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Continuous Operations Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Net Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Bottom Line Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Current Ratio | 2.260 | 1.312 | 1.239 | 5.454 | 11.499 | |
| Quick Ratio | 2.201 | 1.091 | 0.836 | 5.025 | 10.989 | |
| Solvency Ratio | -1.765 | -1.625 | -1.745 | -1.790 | -1.765 | |
| Cash Ratio | 2.135 | 1.027 | 0.742 | 4.861 | 9.159 | |
| Price To Earnings Ratio | -1.467 | -2.827 | -2.061 | -4.252 | -14.186 | |
| Price To Earnings Growth Ratio | 0.027 | 0.074 | 0.125 | 0.686 | -1.102 | |
| Forward Price To Earnings Growth Ratio | 0.027 | 0.074 | 0.125 | 0.686 | -1.102 | |
| Price To Earnings Diluted Ratio | -1.467 | -2.827 | -2.061 | -4.252 | -14.201 | |
| Price To Earnings Diluted Growth Ratio | 0.027 | 0.074 | 0.125 | 0.697 | -1.114 | |
| Price To Book Ratio | 2.338 | 5.898 | 5.047 | 4.974 | 9.485 | |
| Price To Sales Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Price To Free Cash Flow Ratio | -0.002 | -4.014 | -2.872 | -8.475 | -19.271 | |
| Price To Operating Cash Flow Ratio | -0.002 | -4.034 | -2.919 | -8.771 | -28.543 | |
| Debt To Assets Ratio | 0.333 | 0.431 | 0.445 | 0.303 | 0.211 | |
| Debt To Equity Ratio | 0.588 | 0.903 | 1.027 | 0.476 | 0.283 | |
| Debt To Capital Ratio | 0.370 | 0.475 | 0.507 | 0.322 | 0.220 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.764 | 2.098 | 2.310 | 1.571 | 1.342 | |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Ratio | -3,336.826 | -4.075 | -4.090 | -3.911 | -4.772 | |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.002 | 1.005 | 1.016 | 1.035 | 1.481 | |
| Debt Service Coverage Ratio | -32.171 | -29.779 | -43.407 | -29.408 | -28.697 | |
| Interest Coverage Ratio | -38.231 | -35.341 | -46.602 | -33.360 | -31.493 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -1,824.373 | -1.619 | -1.684 | -1.192 | -1.176 | |
| Capital Expenditure Coverage Ratio | -449.231 | -198.274 | -61.378 | -28.596 | -2.078 | |
| Dividend Paid And Capex Coverage Ratio | -449.231 | -198.274 | -61.378 | -28.596 | -2.078 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -1.712 | -3.727 | -2.596 | -4.801 | -15.650 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 0.0% |
| Ebit Margin | 0.0% | 0.0% | 0.0% |
| Ebitda Margin | 0.0% | 0.0% | 0.0% |
| Operating Profit Margin | 0.0% | 0.0% | 0.0% |
| Pretax Profit Margin | 0.0% | 0.0% | 0.0% |
| Continuous Operations Profit Margin | 0.0% | 0.0% | 0.0% |
| Net Profit Margin | 0.0% | 0.0% | 0.0% |
| Bottom Line Profit Margin | 0.0% | 0.0% | 0.0% |
| Current Ratio | 2.260 | ▲0.948 | ▼-2.092 |
| Quick Ratio | 2.201 | ▲1.110 | ▼-1.827 |
| Solvency Ratio | -1.765 | ▼-0.140 | ▼-0.027 |
| Cash Ratio | 2.135 | ▲1.108 | ▼-1.450 |
| Price To Earnings Ratio | -1.467 | ▲1.359 | ▲3.491 |
| Price To Earnings Growth Ratio | 0.027 | ▼-0.047 | ▲0.066 |
| Forward Price To Earnings Growth Ratio | 0.027 | ▼-0.047 | ▲0.066 |
| Price To Earnings Diluted Ratio | -1.467 | ▲1.359 | ▲3.494 |
| Price To Earnings Diluted Growth Ratio | 0.027 | ▼-0.047 | ▲0.066 |
| Price To Book Ratio | 2.338 | ▼-3.559 | ▼-3.210 |
| Price To Sales Ratio | 0.000 | 0.000 | 0.000 |
| Price To Free Cash Flow Ratio | -0.002 | ▲4.012 | ▲6.925 |
| Price To Operating Cash Flow Ratio | -0.002 | ▲4.032 | ▲8.852 |
| Debt To Assets Ratio | 0.333 | ▼-0.097 | ▼-0.011 |
| Debt To Equity Ratio | 0.588 | ▼-0.315 | ▼-0.067 |
| Debt To Capital Ratio | 0.370 | ▼-0.104 | ▼-0.009 |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 |
| Financial Leverage Ratio | 1.764 | ▼-0.333 | ▼-0.053 |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Ratio | -3336.826 | ▼-3332.750 | ▼-2666.091 |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | 0.000 |
| Free Cash Flow Operating Cash Flow Ratio | 1.002 | ▼-0.003 | ▼-0.106 |
| Debt Service Coverage Ratio | -32.171 | ▼-2.391 | ▲0.522 |
| Interest Coverage Ratio | -38.231 | ▼-2.890 | ▼-1.226 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Coverage Ratio | -1824.373 | ▼-1822.754 | ▼-1458.364 |
| Capital Expenditure Coverage Ratio | -449.231 | ▼-250.957 | ▼-301.320 |
| Dividend Paid And Capex Coverage Ratio | -449.231 | ▼-250.957 | ▼-301.320 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -1.712 | ▲2.015 | ▲3.985 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $37.3M | $75.9M | $66.7M | $160.0M | $536.2M | |
| Enterprise value | $35.7M | $82.8M | $76.1M | $152.6M | $516.2M | |
| EV / Sales | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | |
| EV / Op. cash flow | -0.00x | -4.40x | -3.33x | -8.37x | -27.47x | |
| EV / Free cash flow | -0.00x | -4.38x | -3.28x | -8.08x | -18.55x | |
| EV / EBITDA | -1.71x | -3.73x | -2.60x | -4.80x | -15.65x | |
| Net debt / EBITDA | 0.07x | -0.31x | -0.32x | 0.23x | 0.61x | |
| Current ratio | 2.26x | 1.31x | 1.24x | 5.45x | 11.50x | |
| Income quality | 0.67x | 0.70x | 0.71x | 0.50x | 0.52x | |
| Graham net-net | -$0 | -$4 | -$8 | $4 | $18 | |
| Tax burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Interest burden | 102.6% | 102.8% | 102.8% | 103.0% | 103.3% | |
| Working capital | $6.5M | $1.4M | $1.3M | $20.8M | $41.3M | |
| Invested capital | $12.91B | $18.6M | $22.5M | $45.7M | $70.0M | |
| Return on assets | -90.3% | -99.7% | -106.0% | -72.6% | -47.9% | |
| Operating ROA | -90.0% | -91.6% | -77.7% | -57.1% | -62.2% | |
| Return on tangible assets | -90.6% | -100.4% | -106.7% | -72.9% | -48.1% | |
| Return on equity | -159.2% | -209.2% | -244.9% | -114.1% | -64.3% | |
| Return on invested capital | -97.4% | -107.1% | -117.0% | -75.8% | -49.8% | |
| Return on capital employed | -107.8% | -117.8% | -126.2% | -78.6% | -50.3% | |
| Earnings yield | -68.1% | -35.5% | -48.5% | -22.9% | -6.8% | |
| Free cash flow yield | -45983.8% | -24.9% | -34.8% | -11.8% | -5.2% | |
| Capex / Op. cash flow | -0.2% | -0.5% | -1.6% | -3.5% | -48.1% | |
| Capex / Depreciation | 1.0% | 2.4% | 9.4% | 16.7% | 405.1% | |
| Capex / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| SG&A / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| R&D / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Stock comp / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Intangibles / Total assets | 0.4% | 0.6% | 0.6% | 0.4% | 0.4% | |
| Days sales outstanding | 0d | 0d | 0d | 0d | 0d | |
| Days payables outstanding | 24d | 133d | 33d | 0d | 0d | |
| Operating cycle | 7d | 94d | 37d | 0d | 0d | |
| Cash conversion cycle | -17d | -39d | 4d | 0d | 0d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-08-17 CEL-SCI Reports Fiscal Third Quarter 2026 Results VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI reported financial results for three months ended June 30, 2026, as well as key recent corporate and clinical developments for Multikine.
- 2026-08-04 CEL-SCI Study Published in Peer-Reviewed Oral Oncology Supports Multikine''s Biomarker Strategy and Potential Overall Survival Benefit Ahead of Head and Neck Cancer Confirmatory Registration Study VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI study published in peer-reviewed Oral Oncology supports Multikine''s biomarker strategy and potential overall survival benefit.
- 2026-07-30 Leading Oncology Journal Accepts For Publication New CEL-SCI Multikine Phase 3 Data Demonstrating Overall Survival Benefit in Underserved Head and Neck Cancer Patients VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--Leading oncology journal accepts for publication new CEL-SCI Multikine Phase 3 data.
- 2026-07-13 CEL-SCI to Launch FDA Registration-Enabling Phase 3 Confirmatory Study to Bring Multikine® to Market for Newly Diagnosed Head and Neck Cancer VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI to launch FDA Registration-Enabling Phase 3 Confirmatory Study to bring Multikine to Market for newly diagnosed head and neck cancer.
- 2026-06-24 CEL-SCI and Saudi Amarox Hold Strategic Agreement Signing Ceremony at BIO 2026, Advancing U.S.–Saudi Cooperation in Cancer Care VIENNA, Va.--(BUSINESS WIRE)---- $CVM #BIO2026--CEL-SCI and Saudi Amarox Hold Strategic Agreement Signing Ceremony at BIO 2026, Advancing U.S.–Saudi Cooperation in Cancer Care.
- 2026-06-16 CEL-SCI Announces Closing of Offering VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI announces closing of offering.
- 2026-06-16 CEL-SCI Advances Multikine® Immunotherapy for Head and Neck Cancer Through Dual U.S. Registration Study and Saudi Market Entry Strategy VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI advances Multikine immunotherapy for Head and Neck Cancer through dual U.S. registration study and Saudi market entry strategy.
- 2026-06-14 CEL-SCI Corporation Announces Pricing of Offering VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI Corporation announces pricing of offering.
- 2026-06-12 CEL-SCI and Saudi Amarox to Conduct Signing Ceremony at BIO 2026 for Strategic Agreement to Advance Commercialization and Distribution of Multikine® in Saudi Arabia VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI and Saudi Amarox to conduct signing ceremony at BIO 2026 for Strategic Agreement to advance commercialization and distribution of Multikine.